Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00871585
Other study ID # NIS-OHR-CAS-2008/1
Secondary ID
Status Completed
Phase N/A
First received March 27, 2009
Last updated April 14, 2010
Start date March 2009
Est. completion date January 2010

Study information

Verified date April 2010
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Croatia: Agency for Medicinal Product and Medical Devices
Study type Observational

Clinical Trial Summary

Prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical or surgical castration and bicalutamide according to routine medical practice in Croatia. The main aim is to evaluate change of PSA level and prescribing practices based on prostate cancer stage.


Recruitment information / eligibility

Status Completed
Enrollment 340
Est. completion date January 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender Male
Age group 40 Years and older
Eligibility Inclusion Criteria:

- Patients with diagnosis of advanced prostate cancer

- Patients who are already treated with bicalutamide for at least 4 weeks and maximum 12 weeks

- Patients capable of signing ICF

Exclusion Criteria:

- Patients with hypersensitivity to bicalutamide

- Patients on therapy with terfenadin, astemizol or cisapride

- Participation in a clinical study during the last 30 days

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Croatia Research Site Cakovec
Croatia Research Site Dubrovnik
Croatia Research Site Karlovac
Croatia Research Site Pula
Croatia Research Site Rijeka
Croatia Research Site Sibenik
Croatia Research Site Sisak
Croatia Research Site Slavonski brod
Croatia Research Site Split
Croatia Research Site Vinkovci
Croatia Research Site Virovitica
Croatia Research Site Vukovar
Croatia Research Site Zabok
Croatia Research Site Zadar
Croatia Research Site Zagreb

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Croatia, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate change in PSA level following 4-9 months of bicalutamide therapy PSA - 2 measures (at the time of bicalutamdie introduction and 4-9 m following bicalutamide) No
Secondary bicalutamide prescribing practice based on prostate cancer stage 1 measure (at the time of bicalutamde th introduction) No
Secondary to evaluate PSA level after 4-12 weeks of bicalutamide therapy PSA - 1 measures (1-3 m following bicalutamide) No
Secondary to asses time to disease progression based on PSA values PSA - 3 measures (at the time of bicalutamdie introduction, 1-3 m and 4-9 m following bicalutamide) No
Secondary to evaluate percentage of patients with disease progression 2 measures at 1st and 2nd visit No
Secondary to evaluate withdrawals due to adverse events 2 measures, at 1st and 2nd visit No
Secondary to evaluate withdrawals due to Croatian Institute for Health Insurance guidelines for bicalutamide prescription 2 measures, at 1st and 2nd visit No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06006104 - Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer Phase 1/Phase 2
Recruiting NCT03936218 - Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer Phase 3
Completed NCT02234089 - Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
Completed NCT01078545 - Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS) N/A
Active, not recruiting NCT03511196 - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Early Phase 1
Recruiting NCT05942001 - Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1
Active, not recruiting NCT04117594 - Whole Body Magnetic Resonance Imaging Study
Not yet recruiting NCT06369246 - PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer Phase 2
Completed NCT01383863 - A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
Completed NCT03651271 - Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer Phase 2
Active, not recruiting NCT05590793 - Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate Phase 3
Recruiting NCT06095089 - A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer Phase 1
Active, not recruiting NCT02787837 - PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.
Active, not recruiting NCT02362620 - PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.
Recruiting NCT05800665 - A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer Phase 1
Recruiting NCT03938649 - SRAM study_Postate Cancer Phase 2
Active, not recruiting NCT02922218 - PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.
Not yet recruiting NCT06335914 - Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer N/A
Terminated NCT03577028 - Study of HPN424 in Patients With Advanced Prostate Cancer Phase 1/Phase 2
Terminated NCT03971110 - A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. Phase 4